Dianthus Therapeutics (DNTH) Non-Current Deffered Revenue (2018 - 2025)
Historic Non-Current Deffered Revenue for Dianthus Therapeutics (DNTH) over the last 7 years, with Q3 2025 value amounting to $6.1 million.
- Dianthus Therapeutics' Non-Current Deffered Revenue rose 84812.5% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year increase of 84812.5%. This contributed to the annual value of $1.9 million for FY2024, which is 15923.91% up from last year.
- Dianthus Therapeutics' Non-Current Deffered Revenue amounted to $6.1 million in Q3 2025, which was up 84812.5% from $1.8 million recorded in Q2 2025.
- In the past 5 years, Dianthus Therapeutics' Non-Current Deffered Revenue ranged from a high of $6.1 million in Q3 2025 and a low of $640000.0 during Q3 2024
- Over the past 4 years, Dianthus Therapeutics' median Non-Current Deffered Revenue value was $768000.0 (recorded in 2022), while the average stood at $1.6 million.
- Per our database at Business Quant, Dianthus Therapeutics' Non-Current Deffered Revenue crashed by 1409.4% in 2024 and then skyrocketed by 84812.5% in 2025.
- Over the past 4 years, Dianthus Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $791000.0 in 2022, then dropped by 6.95% to $736000.0 in 2023, then surged by 159.24% to $1.9 million in 2024, then surged by 218.03% to $6.1 million in 2025.
- Its last three reported values are $6.1 million in Q3 2025, $1.8 million for Q2 2025, and $1.9 million during Q1 2025.